key: cord-0707900-4lgohe4a
authors: de Vries, Gerard; Boogaard, Jossy van den; Abubakar, Ibrahim
title: The importance of systematic data collection, monitoring and evaluation of tuberculosis screening programmes of migrants arriving in low-incidence countries
date: 2021-04-27
journal: Lancet Reg Health West Pac
DOI: 10.1016/j.lanwpc.2021.100154
sha: 063e7cef6c2043c1380843e2d008708680593de2
doc_id: 707900
cord_uid: 4lgohe4a

nan

undertaken offshore and one third (33.7%) within Australia. Visa applicants were predominantly young adults from Asian countries. Analysis of the 1263 cases diagnosed by the screening programme, revealed several important findings. First, the overall prevalence was relatively low with 53.0 cases per 10 0.0 0 0 applicants (95% CI 50.2-56.1), i.e. 1887 persons needed to be screened to detect one case. The TB prevalence among visa applicants differed substantially by countries categorized according to WHO-estimated prevalence, and varied from 6.8 per 10 0.0 0 0 (95% CI 4.5-10.2) for migrants from countries with a TB prevalence of < 40 per 10 0,0 0 0 to 198.4 (95% CI 180.7-217.7) for migrants from countries with a prevalence ≥350 per 10 0,0 0 0. Second, the prevalence was 8.0 (6.5-9.9) times higher in humanitarian visa applicants (183 per 10 0,0 0 0) compared to temporary visa applicants, and 25.7 (21.9-30.2) fold higher in people with past TB treatment (2141 per 10 0,0 0 0). Third, age-standardized TB prevalence in offshore applicants closely matched the WHO-estimated TB prevalence in the countries of origin.

The study of Trauer and colleagues presents to our knowledge the largest dataset on TB screening of migrants to a single country, and nicely illustrates the value of systematic data collection, monitoring and evaluation of screening. In Europe, four countries (Italy, the Netherlands, Sweden and United Kingdom) have recently set up a European database on TB and Latent TB Infection (LTBI) screening of migrants to provide greater statistical power and to contribute to migrant TB screening evidence. This database includes modules on eligible migrants for screening, screening data, linkage to care, treatment completion and reactivation (the latter only for LTBI diagnoses) [5] .

The low TB prevalence among visa applicants found by Trauer and colleagues impacts the effectiveness and cost-effectiveness of the intervention. Their study provides suggestions to improve the effectiveness, e.g. by limiting screening to migrants from countries with a TB prevalence above a certain cut-off, as is practised in most European countries [ 6 , 7 ] . The observation that humanitarian applicants, such as refugees and asylum seekers, have a high risk for TB clearly indicates that these individuals need priority in a TB prevention and care programme. Their study is not reporting on linkage-to-care issues which may not be available for persons diagnosed with TB outside Australia, but could be more readily available for those diagnosed in Australia. It is important to report on all steps of the screening process, from eligibility of persons for screening to the treatment completion of people diagnosed with TB.

Trauer and colleagues also raise the importance of reactivation of overseas-acquired LTBI, and scaling up post-migration interventions to reduce the TB burden. The epidemiology in low-incidence countries indeed shows that a substantial number and proportion of migrants develop TB in the host country several months or years after migration [ 8 , 9 ] . In Australia, LTBI testing and treatment of migrants is currently limited to children aged two to ten years and to older migrants with a history of close contact with a TB patient, but could be extended to people from high TB burden countries to move towards TB elimination.

Trauer and colleagues conclude that support for TB control programmes overseas and preventive interventions are likely to have the greatest impact on the TB burden in high-income countries. We fully agree with them, that these investments will highly benefit the people in the countries concerned, as well as the highincome countries that may receive migrants from these countries in time [10] .

IA acted as WHO STAG Chair ended in 2019.

The UCL-lancet commission on migration and health: the health of a world on the move

European Centre for Disease Prevention and Control Assessing the burden of key infectious diseases affecting migrant populations in the EU/EEA. Stockholm: ECDC

WHO consolidated guidelines on tuberculosis Module 2: screening -systematic screening for tuberculosis disease. Geneva: World Health Organization

Tuberculosis in migrants to Australia: outcomes of a national screening program

Building a European database to gather multi-country evidence on active and latent TB screening for migrants

Pre-entry screening programmes for tuberculosis in migrants to low-incidence countries: a systematic review and meta-analysis

Tuberculosis and latent tuberculous infection screening of migrants in Europe: comparative analysis of policies, surveillance systems and results

High incidence of active tuberculosis in asylum seekers from Eritrea and Somalia in the first 5 years after arrival in the Netherlands

Long-term risk of tuberculosis among migrants according to migrant status: a cohort study

Impact of effective global tuberculosis control on health and economic outcomes in the United States